Respiratory syncytial virus–Host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life

Pediatric Allergy and Immunology

Volumn 28, Issue 4, 2017, Pages 320-331

  Rossi, Giovanni A ^a   Colin, Andrew A ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

adaptive immune response; asthma; bronchial hyperreactivity; bronchiolitis; nasopharyngeal aspirate; neurogenic inflammation; viral infections

Indexed keywords

ANTIVIRUS AGENT; HOST FACTOR;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; DOWN REGULATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INNATE IMMUNITY; MORBIDITY; NEUROGENIC INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VIRAL BRONCHIOLITIS; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS; WHEEZING; ADULT; CHILD; COMORBIDITY; DISEASE EXACERBATION; GENETIC PREDISPOSITION; HOST PARASITE INTERACTION; IMMUNOLOGY; IMMUNOMODULATION; INFANT; PATHOGENICITY; PHYSIOLOGY; PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; VIROLOGY; VIRULENCE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; BRONCHIOLITIS, VIRAL; CHILD; COMORBIDITY; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HOST-PARASITE INTERACTIONS; HUMANS; INFANT; NEUROIMMUNOMODULATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT DISEASES; VIRAL LOAD; VIRULENCE; VIRUS REPLICATION;

EID: 85018256473     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12716     Document Type: Review

References (104)

1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986: 140: 543–6.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010: 375: 1545–55.
3. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000: 137: 865–70.
4. Carbonell-Estrany X, Figueras-Aloy J, Law BJ, et al. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004: 23: S193–201.
5. Rossi GA, Medici MC, Arcangeletti MC, et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007: 166: 1267–72.
6. Weisman LE. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Pediatr Infect Dis J 2003: 22: S33–9.
7. Wang EEL, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of morbidity and risk factors with RSV disease. J Pediatr 1995: 126: 212–9.
8. Régnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J 2013: 32: 820–6.
9. Carroll KN, Wu P, Gebretsadik T, et al. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J Allergy Clin Immunol 2009: 123: 1055–61.
10. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999: 354: 541–5.
11. Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010: 65: 1045–52.
12. Korppi M, Piippo-Savolainen E, Korhonen K, Remes S. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol 2004: 38: 155–60.
13. Backman K, Piippo-Savolainen E, Ollikainen H, Koskela H, Korppi M. Adults face increased asthma risk after infant RSV bronchiolitis and reduced respiratory health-related quality of life after RSV pneumonia. Acta Paediatr 2014: 103: 850–5.
14. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013: 368: 1791–9.
15. Simões EA, Carbonell-Estrany X, Rieger CH, et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010: 126: 256–62.
16. Troy NM, Bosco A. Respiratory viral infections and host responsesinsights from genomics. Respir Res 2016: 17: 156.
17. Lay MK, González PA, León MA, et al. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect 2013: 15: 230–42.
18. Rossi GA, Colin AA. Infantile respiratory syncytial virus and human rhinovirus infections: respective role in inception and persistence of wheezing. Eur Respir J 2015: 45: 774–89.
19. Arruvito L, Raiden S, Geffner J. Host response to respiratory syncytial virus infection. Curr Opin Infect Dis 2015: 28: 259–66.
20. Fuentes S, Tran KC, Luthra P, Teng MN, He B. Function of the respiratory syncytial virus small hydrophobic protein. J Virol 2007: 81: 8361–6.
21. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007: 20: 108–19.
22. McNamara PS, Flanagan BF, Selby AM, Hart CA, Smyth RL. Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. Eur Respir J 2004: 23: 106–12.
23. Bueno SM, González PA, Pacheco R, et al. Host immunity during RSV pathogenesis. Int Immunopharmacol 2008: 8: 1320–9.
24. Ioannidis I, McNally B, Willette M, Peeples ME, et al. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J Virol 2012: 86: 5422–36.
25. Lee HC, Headley MB, Loo YM, et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol 2012: 130: 1187–96.
26. Rudd BD, Smit JJ, Flavell RA, et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol 2006: 176: 1937–42.
27. Goto-Sugai K, Tsukagoshi H, Mizuta K, et al. Genotyping and phylogenetic analysis of the major genes in respiratory syncytial virus isolated from infants with bronchiolitis. Jpn J Infect Dis 2010: 63: 393–400.
28. Scagnolari C, Midulla F, Selvaggi C, et al. Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. Med Microbiol Immunol 2012: 201: 311–7.
29. Rossi GA, Silvestri M, Colin AA. Respiratory syncytial virus infection of airway cells: role of microRNAs. Pediatr Pulmonol 2015: 50: 727–32.
30. Bakre A, Mitchell P, Coleman JK, et al. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. J Gen Virol 2012: 93: 2346–56.
31. Inchley CS, Sonerud T, Fjærli HO, Nakstad B. Nasal mucosal microRNA expression in children with respiratory syncytial virus infection. BMC Infect Dis 2015: 15: 150.
32. Othumpangat S, Walton C, Piedimonte G. MicroRNA-221 modulates RSV replication in human bronchial epithelium by targeting NGF expression. PLoS One 2012: 7: e30030.
33. Liu S, Gao L, Wang X, Xing Y. Respiratory syncytial virus infection inhibits TLR4 signaling via up-regulation of miR-26b. Cell Biol Int 2015: 39: 1376–83.
34. Shingai M, Azuma M, Ebihara T, et al. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-β induction. Int Immunol 2008: 20: 1169–80.
35. Lifland AW, Jung J, Alomas E, Zurla C, Crowe JE Jr, Santangelo PJ. Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS. J Virol 2012: 86: 8245–58.
36. Swedan S, Musiyenko A, Barik S. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol 2009: 83: 9682–93.
37. Choi EH, Lee HJ, Chanock SJ. Human genetics and respiratory syncytial virus disease: current findings and future approaches. Curr Top Microbiol Immunol 2013: 372: 121–37.
38. Tal G, Mandelberg A, Dalal I, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004: 189: 2057–63.
39. Tulic MK, Hurrelbrink RJ, Prêle CM, et al. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J Immunol 2007: 179: 132–40.
40. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients 2015: 7: 4240–70.
41. Kresfelder TL, Janssen R, Bont L, Pretorius M, Venter M. Confirmation of an association between single nucleotide polymorphisms in the VDR gene with respiratory syncytial virus related disease in South African children. J Med Virol 2011: 83: 1834–40.
42. McNally JD, Sampson M, Matheson LA, Hutton B, Little J. Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis. Pediatr Pulmonol 2014: 49: 790–9.
43. Ampuero S, Luchsinger V, Tapia L, Palomino MA, Larrañaga CE. SP-A1, SP-A2 and SP-D gene polymorphisms in severe acute respiratory syncytial infection in Chilean infants. Infect Genet Evol 2011: 11: 1368–77.
44. Liu W, Bentley CM, Floros J. Study of human SP-A SP-B and SP-D loci: allele frequencies, linkage disequilibrium and heterozygosity in different races and ethnic groups. BMC Genet 2003: 11: 13–21.
45. Rämet M, Haataja R, Marttila R, Floros J, Hallman M. Association between the surfactant A (SP-A) gene locus and respiratory-distress syndrome in the Finnish population. Am J Hum Genet 2000: 66: 1569–79.
46. Liu Y. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001: 106: 259–62.
47. Garg R, Shrivastava P, van Drunen Littel-van den Hurk S. The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development. Expert Rev Vaccines 2012: 11: 1441–57.
48. Muñoz JL, McCarthy CA, Clark ME, Hall CB. Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells. J Virol 1991: 65: 4494–7.
49. DiNapoli JM, Murphy BR, Collins PL, Bukreyev A. Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virol J 2008: 5: 105.
50. Mangodt TC, Van Herck MA, Nullens S, et al. The role of Th17 and Treg responses in the pathogenesis of RSV infection. Pediatr Res 2015: 78: 483–91.
51. Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS. Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol 2009: 83: 3019–28.
52. Durant LR, Makris S, Voorburg CM, Loebbermann J, Johansson C, Openshaw PJ. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol 2013: 87: 10946–54.
53. Stoppelenburg AJ, de Roock S, Hennus MP, Bont L, Boes M. Elevated Th17 response in infants undergoing respiratory viral infection. Am J Pathol 2014: 184: 1274–9.
54. Chiu C, Openshaw PJ. Antiviral B cell and T cell immunity in the lungs. Nat Immunol 2015: 16: 18–26.
55. Hishiki H, Zuercher AW, Valosky J, Coffin SE. Regional differences in the early mucosal immune response induced by primary inoculation of mice with respiratory syncytial virus. Microb Pathog 2004: 36: 141–6.
56. Bartz H, Turkel O, Hoffjan S, Rothoeft T, Gonschorek A, Schauer U. Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-γ in naïve T cells. Immunology 2003: 109: 49–57.
57. Marr N, Wang TI, Kam SH, et al. Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. J Immunol 2014: 192: 948–57.
58. Beyer M, Bartz H, Hörner K, Dotths S, Koerner-Rettberg C, Schwarze J. Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection. J Allergy Clin Immunol 2004: 113: 127–33.
59. Ruckwardt TJ, Malloy AM, Morabito KM, Graham BS. Quantitative and qualitative deficits in neonatal lung-migratory dendritic cells impact the generation of the CD8+ T cell response. PLoS Pathog 2014: 10: e1003934.
60. Kerrin A, Fitch P, Errington C, et al. Differential lower airway dendritic cell patterns may reveal distinct endotypes of RSV bronchiolitis. Thorax 2016: pii: thoraxjnl-2015-207358. doi: 10.1136/thoraxjnl-2015-207358. [Epub ahead of print]
61. Remot A, Descamps D, Jouneau L, et al. Flt3 ligand improves the innate response to respiratory respiratory syncytial virus and limits lung disease upon RSV reexposure in neonate mice. Eur J Immunol 2016: 46: 874–84.
62. Wang H, Peters N, Laza-Stanca V, Nawroly N, Johnston SL, Schwarze J. Local CD11c+ MHC class II- precursors generate lung dendritic cells during respiratory viral infection, but are depleted in the process. J Immunol 2006: 177: 2536–42.
63. Morris S, Swanson MS, Lieberman A, et al. Autophagy-mediated dendritic cell activation is essential for innate cytokine production and APC function with respiratory syncytial virus responses. J Immunol 2011: 187: 3953–61.
64. Reed M, Morris SH, Jang S, Mukherjee S, Yue Z, Lukacs NW. Autophagy-inducing protein beclin-1 in dendritic cells regulates CD4 T cell responses and disease severity during respiratory syncytial virus infection. J Immunol 2013: 191: 2526–37.
65. Reed M, Morris SH, Owczarczyk AB, Lukacs NW. Deficiency of autophagy protein Map1-LC3b mediates IL-17-dependent lung pathology during respiratory viral infection via ER stress-associated IL-1. Mucosal Immunol 2015: 8: 1118–30.
66. Owczarczyk AB, Schaller MA, Reed M, Rasky AJ, Lombard DB, Lukacs NW. Sirtuin 1 regulates dendritic cell activation and autophagy during respiratory syncytial virus-induced immune responses. J Immunol 2015: 195: 1637–46.
67. Raes M, Peeters V, Alliet P, et al. Peripheral blood T and B lymphocyte subpopulations in infants with acute respiratory syncytial virus brochiolitis. Pediatr Allergy Immunol 1997: 8: 97–102.
68. Kim KH, Lee YT, Hwang HS, et al. Virus-like particle vaccine containing the F protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector T cells. J Virol 2015: 89: 11692–705.
69. Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997: 186: 421–32.
70. Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4+ T cells. Immunity 2001: 15: 637–46.
71. Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 1999: 73: 8485–95.
72. Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 2006: 176: 1600–8.
73. Johnson TR, Varga SM, Braciale TJ, Graham BS. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol 2004: 78: 8753–60.
74. Tripp RA, Moore D, Winter J, Anderson LJ. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J Virol 2000: 74: 1614–22.
75. Thomsen SF, Stensballe LG, Skytthe A, Kyvik KO, Backer V, Bisgaard H. Increased concordance of severe respiratory syncytial virus infection in identical twins. Pediatrics 2008: 121: 493–6.
76. Faber TE, Schuurhof A, Vonk A, Koppelman GH, et al. IL1RL1 gene variants and nasopharyngeal IL1RL-a levels are associated with severe RSV bronchiolitis: a multicenter cohort study. PLoS One 2012: 7: e34364.
77. Wilson J, Rowlands K, Rockett K, et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. J Infect Dis 2005: 191: 1705–9.
78. Ermers MJ, Janssen R, Onland-Moret NC, et al. IL-10 family member genes IL19 and IL20 are associated with recurrent wheeze after respiratory syncytial virus bronchiolitis. Pediatr Res 2011: 70: 518–23.
79. Tian M, Liu F, Wen GY, Shi SY, Chen RH, Zhao DY. Effect of variation in RANTES promoter on serum RANTES levels and risk of recurrent wheezing after RSV bronchiolitis in children from Han, Southern China. Eur J Pediatr 2009: 168: 963–7.
80. Amanatidou V, Sourvinos G, Apostolakis S, Neonaki P, et al. RANTES promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis. Pediatr Infect Dis J 2008: 27: 38–42.
81. Forton JT, Rowlands K, Rockett K, et al. Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster. Thorax 2009: 64: 345–52.
82. Schuurhof A, Bont L, Siezen CL, et al. Interleukin-9 polymorphism in infants with respiratory syncytial virus infection: an opposite effect in boys and girls. Pediatr Pulmonol 2010: 45: 608–13.
83. Murphy BR, Graham BS, Prince GA, et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol 1986: 23: 1009–14.
84. Brown PM, Schneeberger DL, Piedimonte G. Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity. Paediatr Respir Rev 2015: 16: 232–40.
85. Tortorolo L, Langer A, Polidori G, et al. Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med 2005: 172: 233–7.
86. Zang N, Li S, Li W, Xie X, Ren L, et al. Resveratrol suppresses persistent airway inflammation and hyperresponsivess might partially via nerve growth factor in respiratory syncytial virus-infected mice. Int Immunopharmacol 2015: 28: 121–8.
87. Li QG, Wu XR, Li XZ, et al. Neural-endocrine mechanisms of respiratory syncytial virus-associated asthma in a rat model. Genet Mol Res 2012: 11: 2780–9.
88. Rohwedder A, Keminer O, Forster J, Schneider K, Schneider E, Werchau H. Detection of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction. J Med Virol 1998: 54: 320–7.
89. Menchise A. Myocarditis in the setting of RSV bronchiolitis. Fetal Pediatr Pathol 2011: 30: 64–8.
90. Kawashima H, Ioi H, Ushio M, Yamanaka G, Matsumoto S, Nakayama T. Cerebrospinal fluid analysis in children with seizures from respiratory syncytial virus infection. Scand J Infect Dis 2009: 41: 228–31.
91. Nadal D, Wunderli W, Meurmann O, Briner J, Hirsig J. Isolation of respiratory syncytial virus from liver tissue and extrahepatic biliary atresia material. Scand J Infect Dis 1990: 22: 91–3.
92. Das B, Kashino SS, Pulu I, et al. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 2013: 5: 170.
93. Rezaee F, Gibson LF, Piktel D, Othumpangat S, Piedimonte G. Respiratory syncytial virus infection in human bone marrow stromal cells. Am J Respir Cell Mol Biol 2011: 45: 277–86.
94. Torgerson DG, Giri T, Druley TE, et al. Pooled sequencing of candidate genes implicates rare variants in the development of asthma following severe RSV bronchiolitis in infancy. PLoS One 2015: 10: e0142649.
95. Bertrand P, Lay MK, Piedimonte G, et al. Elevated IL-3 and IL-12p40 levels in the lower airway of infants with RSV-induced bronchiolitis correlate with recurrent wheezing. Cytokine 2015: 76: 417–23.
96. Bacharier LB, Cohen R, Schweiger T, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2012: 130: 91–100.
97. Schuurhof A, Janssen R, de Groot H, et al. Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze. Respir Res 2011: 12: 121.
98. Gern JE, Rosenthal LA, Sorkness RL, Lemanske RF Jr. Effects of viral respiratory infections on lung development and childhood asthma. J Allergy Clin Immunol 2005: 115: 668–74.
99. Micera A, Vigneti E, Pickholtz D, et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci USA 2001: 98: 6162–7.
100. Esposito S, Pietro GD. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline. Future Microbiol 2016: 11: 1479–90.
101. Mazur NI, Martinón-Torres F, Baraldi E, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med 2015: 3: 888–900.
102. Saso A, Kampmann B. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? Lancet Infect Dis 2016: 16: e153–63.
103. Jaberolansar N, Toth I, Young PR, Skwarczynski M. Recent advances in the development of subunit-based RSV vaccines. Expert Rev Vaccines 2016: 15: 53–68.
104. Cox R, Plemper RK. Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opin Drug Discov 2016. [Epub ahead of print]